{"title":"The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19.","authors":"Wen-Kuei Chang, Chieh-Jen Wang, Tung-Hu Tsai, Fang-Ju Sun, Chao-Hsien Chen, Kuan-Chih Kuo, Hsin-Pei Chung, Yen-Hsiang Tang, Yen-Ting Chen, Kuo-Lun Wu, Jou-Chun Wu, Chang-Yi Lin, Hai-Bo Zhang","doi":"10.1080/14787210.2024.2313054","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19.</p><p><strong>Research design and methods: </strong>We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 1:2 ratio was performed to reduce confounding factors.</p><p><strong>Results: </strong>A total of 201 patients were analyzed. The experimental group (<i>n</i> = 67) received NRICM101 and standard care, while the control group (<i>n</i> = 134) received standard care alone. No significant differences were observed in mortality (10.4% vs. 14.2%), intubation (13.8% vs. 11%), time to intubation (10 vs. 11 days), mechanical ventilation days (0 vs. 9 days), or oxygen support duration (6 vs. 5 days). However, the experimental group had a shorter length of hospitalization (odds ratio = 0.12, <i>p</i> = 0.043) and fewer mechanical ventilation days (odds ratio = 0.068, <i>p</i> = 0.008) in initially severe cases, along with an increased diarrhea risk (<i>p</i> = 0.035).</p><p><strong>Conclusion: </strong>NRICM101 did not reduce in-hospital mortality. However, it shortened the length of hospitalization and reduced mechanical ventilation days in initially severe cases. Further investigation is needed.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2313054","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19.
Research design and methods: We conducted a retrospective study from 20 April 2021 to 8 July 2021, and evaluated the safety and outcomes (mortality, hospital stay, mechanical ventilation, oxygen support, diarrhea, serum potassium) in COVID-19 patients. Propensity score matching at a 1:2 ratio was performed to reduce confounding factors.
Results: A total of 201 patients were analyzed. The experimental group (n = 67) received NRICM101 and standard care, while the control group (n = 134) received standard care alone. No significant differences were observed in mortality (10.4% vs. 14.2%), intubation (13.8% vs. 11%), time to intubation (10 vs. 11 days), mechanical ventilation days (0 vs. 9 days), or oxygen support duration (6 vs. 5 days). However, the experimental group had a shorter length of hospitalization (odds ratio = 0.12, p = 0.043) and fewer mechanical ventilation days (odds ratio = 0.068, p = 0.008) in initially severe cases, along with an increased diarrhea risk (p = 0.035).
Conclusion: NRICM101 did not reduce in-hospital mortality. However, it shortened the length of hospitalization and reduced mechanical ventilation days in initially severe cases. Further investigation is needed.
期刊介绍:
Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.